Taysha Gene Therapies Reports Initial Clinical Data from First Adult Rett Syndrome Patient Dosed in REVEAL Phase 1/2 Trial and Provides Corporate Update with Second Quarter 2023 Financial ResultsGlobeNewsWire • 08/14/23
Taysha Gene Therapies Announces Positive Recommendation from Independent Data Monitoring Committee of REVEAL Phase 1/2 Trial in Rett SyndromeGlobeNewsWire • 07/31/23
Taysha Gene Therapies Provides Clinical Updates for Investigational Programs TSHA-120 in Giant Axonal Neuropathy (GAN) and TSHA-102 in Rett Syndrome at R&D DayGlobeNewsWire • 06/28/23
Taysha Gene Therapies to Host Virtual R&D Day on Lead Clinical Investigational Programs TSHA-120 in Giant Axonal Neuropathy (GAN) and TSHA-102 in Rett SyndromeGlobeNewsWire • 06/15/23
Taysha Gene Therapies Announces First Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Trial Under Investigation for the Treatment of Rett SyndromeGlobeNewsWire • 06/05/23
Taysha Gene Therapies Presents Preclinical Data on TSHA-102 for Rett Syndrome Demonstrating Cellular Regulation of MeCP2 Expression in Key Mouse Models at the American Society of Gene and Cell Therapy 26th Annual MeetingGlobeNewsWire • 05/19/23
Taysha Gene Therapies Reports First Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/11/23
Taysha Gene Therapies to Release First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 11GlobeNewsWire • 05/04/23
Taysha Gene Therapies Announces Presentation on New Preclinical Data for TSHA-102 in Rett Syndrome at Upcoming American Society of Gene and Cell Therapy 26th Annual MeetingGlobeNewsWire • 04/27/23
Taysha Gene Therapies Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/28/23
Taysha Gene Therapies to Release Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call and Webcast on March 28GlobeNewsWire • 03/15/23
Taysha Gene Therapies Provides Update on TSHA-120 Program in Giant Axonal Neuropathy and a 2023 Corporate OutlookGlobeNewsWire • 01/31/23
Taysha Gene Therapies, Inc. (TSHA) Could Find Support Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 12/01/22
Taysha Gene Therapies to Participate in JMP Securities Hematology and Oncology SummitGlobeNewsWire • 11/29/22
Taysha Gene Therapies: Astellas Throws Lifeline For First Dibs On Rett And GAN ProgramsSeeking Alpha • 11/17/22
Taysha Gene Therapies, Inc. (TSHA) Q3 2022 Results - Earnings Call TranscriptSeeking Alpha • 11/13/22
Taysha Gene Therapies Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/08/22